Recent advances in molecular targeted therapy for metastatic renal cell carcinoma

International Journal of Urology

Volumn 16, Issue 5, 2009, Pages 444-448

  Mizutani, Yoichi ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Molecular targeted therapy; Renal cell carcinoma; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; MOLECULAR THERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PATIENT ASSESSMENT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRIDINES; PYRROLES; SIROLIMUS;

EID: 65449145132     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2009.02277.x     Document Type: Review

References (36)

1. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 1996 35 : 865 75.
2. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma. Cancer 1997 80 : 1198 220.
3. Lam JS, Shvarts O, Leppert JT et al. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J. Urol. 2005 173 : 1853 62. (Pubitemid 40675199)
4. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 2005 353 : 2477 87. (Pubitemid 41770167)
5. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 57 : 4593 9. (Pubitemid 27441066)
6. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001 19 : 843 50. (Pubitemid 32119100)
7. Yang JC, Howorth L, Sherry R et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003 349 : 427 34. (Pubitemid 36910021)
8. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized, double-blind phase III trial. Lancet 2007 370 : 2103 11. (Pubitemid 350296300)
9. Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 2005 23 : 832 41. (Pubitemid 46224183)
10. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 64 : 7099 109. (Pubitemid 39331023)
11. Carlomabno F, Anaganti S, Guida T et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006 98 : 326 34. (Pubitemid 43338212)
12. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 125 34. (Pubitemid 46089673)
13. Tamasker IR, Unnithan J, Garcia JA et al. Thyroid function test (TFT) in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. J. Clin. Oncol. 2007 25 : S246.
14. Szczylik C, Demkow T, Staehler M et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma final results. J. Clin. Oncol. 2007 25 : S241.
15. Knox JJ, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. J. Clin. Oncol. 2007 25 : S237.
16. Stein MN, Flaherty KT. Sorafenib and sunitinib in renal cell carcinoma. Clin. Cancer Res. 2007 13 : 3765 70. (Pubitemid 47037579)
17. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003 9 : 327 37. (Pubitemid 36109749)
18. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alpha in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 115 24. (Pubitemid 46089672)
19. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 2007 99 : 81 5.
20. Tsai KY, Yang CH, Kuo TT et al. Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma. J. Clin. Oncol. 2006 24 : 5786 7.
21. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006 24 : 16 24. (Pubitemid 46630489)
22. Gore ME, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J. Clin. Oncol. 2007 25 : S237.
23. Tamaskar I, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 2008 179 : 81 6. (Pubitemid 350216728)
24. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 2008 26 : 127 31.
25. Chu TF, Rupnick NA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 : 2011 19. (Pubitemid 350236338)
26. Joensuu H. Cardiac toxicity of sunitinib. Lancet 2007 370 : 1978 9. (Pubitemid 350236322)
27. Schmidinger M, Vogl UM, Schukro C et al. Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. J. Clin. Oncol. 2007 25 : 262.
28. Sablin MP, Bouaita L, Balleyguier C et al. Sequential use of sorafenib and sunitinib: retrospective analysis in 90 patients. J. Clin. Oncol. 2007 25 : S244.
29. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J. Clin. Oncol. 2007 25 : S261.
30. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 2006 116 : 2610 21. (Pubitemid 44511625)
31. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 2005 23 : 5474 83. (Pubitemid 46300140)
32. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol. 2007 8 : 975 84. (Pubitemid 47629888)
33. Rini BI, Widing GT, Hudes WM et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J. Clin. Oncol. 2007 25 : S242.
34. Rini BI. Temsirolomus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 2008 14 : 1286 90.
35. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007 356 : 2271 81. (Pubitemid 46849157)
36. Motzer RJ, Escudier B, Oudard S et al. efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008 372 : 449 56.